SCI / RSC 22nd Medicinal Chemistry Symposium

SCI / RSC 22nd Medicinal Chemistry Symposium

Sunday – Wednesday, 10th-13th September, 2023

Churchill College, Cambridge

The organisers invite you to the 22nd SCI-RSC Medicinal Chemistry symposium, Europe’s premier biennial Medicinal Chemistry event, focusing on first disclosures and new strategies in Medicinal Chemistry.

Exhibition and Sponsorship
Churchill College is an ideal venue for exhibitors. All refreshments, the exhibition and posters will be situated in a single area, ensuring excellent access to delegates throughout the meeting.

The exhibition will run alongside the conference during refreshment breaks and poster sessions. Those who wish to exhibit are encouraged to book early to avoid disappointment. Exhibition stands will be available to book via the registration page when registration opens, and the rate will include two stand staff and daytime refreshments.

For further information and prices, please email

Please click here for main conference website.

Confirmed Talks

The discovery of sebetralstat, an oral, small molecule oral plasma kallikrein inhibitor to treat attacks of hereditary angioedema
Rebecca Davie, KalVista

Discovery of reversible highly potent and selective MAGL inhibitors
Uwe Grether, Roche

Discovery and first-time disclosure of NT-0796, a clinical phase NLRP3 inflammasome inhibitor for inflammation
David Harrison, NodThera

LMW inhibitors of IL-1β, from fragment hits to cellular PoC
Konstanze Hurth, Novartis Institutes for BioMedica

Discovery of LAS202051, a potent Acetyl-CoA Carboxylase (ACC) inhibitor for the topical treatment of acne
Jordi Bach Taña, Almirall

Discovery of a novel class of brain penetrant inhibitors of KRAS G12C
Jason Kettle, AstraZeneca

Fadaltran, a Selective Antagonist for the Peripheral AR alpha 2c Receptors: A New Option for the Treatment of Diabetic Foot Ulcers?
Carsten Schmeck, Bayer

Fragment-based drug discovery approaches to the development of protein-protein interaction inhibitors
Dr John Skidmore, The ALBORADA Drug Discovery Institute, University of Cambridge

Plasmepsin X inhibitors with in vivo antimalarial activity
Teresa de Haro Garcia, UCB

Discovery of VX-147 as a Targeted Therapy for APOL1‑mediated Kidney Disease’
Les Dakin, Vertex

Lessons Learnt building the GSK pan-BET bromodomain portfolio
Phil Humphreys, GSK

Gamma Secretase Modulator for the treatment of Alzheimer’s Disease
Rosa Maria Rodriguez Sarmiento, Hoffman La Roche

SAGE-718, a compound in phase II for a variety of CNS indications. (NMDAR PAM)
Matthew Hill

Organising Committee
Nadia Ahmad, Charles River
John Cumming, Roche
Mark Healy, Novartis
Joanne Pinder, Vertex
Jamie Scott, AstraZeneca
Gordon Saxty, NS-MC Consulting
Chris Swain, Cambridge MedChem Consulting
Andrew Williams, Chairman of the RSC BMCS

Secretariat Contact and Further Information
SCI Conference Team
+44 (0)2075981561